本项集中涉及民生药品盐酸罂粟碱注射剂。盐酸罂粟碱注射剂是一种血管扩张药，主要用于治疗脑、心 及外周血管痉挛所致的缺血，肾、胆或胃肠道等内脏痉挛，且在手指显微手术中具有独特疗效，其他血 管扩张药无法对其有效替代。 南都讯 记者黄莉玲 7月23日市场监管总局在官网公布，禁止武汉用通医药有限公司（以下简称武汉用 通）收购山东北大高科华泰制药有限公司（以下简称山东华泰制药）股权案件。 据悉，本案是2008年《中华人民共和国反垄断法》施行以来第四起禁止的经营者集中案件，是第一起对 未达申报标准的经营者集中予以禁止的案件，也是首次要求相关方对已实施的集中采取措施恢复到集中 前状态。 不仅如此，通报还谈及集中后实体具有排除、限制中国境内盐酸罂粟碱注射剂市场竞争的动机，且产生 了排除、限制竞争效果。具体表现为集中后山东华泰制药在下游市场的份额明显提升；盐酸罂粟碱注射 剂价格显著上涨，严重损害下游消费者权益。 官方披露数据显示，2016年9月，武汉用通成为青海制药原料药独家销售商后，原料药价格大幅上涨， 盐酸罂粟碱注射剂价格也随之上涨，2018年平均出厂价格较2017年上涨超过400%。集中完成后，2019 年盐酸罂粟碱注射剂 ...

Core Viewpoint - The State Administration for Market Regulation has prohibited Wuhan Yitong Pharmaceutical Co., Ltd. from acquiring shares of Shandong Huatai Pharmaceutical Co., Ltd. due to antitrust concerns, emphasizing the need to maintain competition in the market for hydrochloride poppy alkaloid injection [1][2] Group 1 - The acquisition was deemed to have an exclusionary and restrictive effect on competition in the hydrochloride poppy alkaloid injection market in China [1] - Wuhan Yitong is required to transfer its indirect holdings in Shandong Huatai Pharmaceutical to an unrelated third party by January 22, 2026, and must not participate in the management of Shandong Huatai during this period [1] - If the share transfer is not completed by the deadline, Wuhan Yitong must apply to the market regulator for an extension and provide reasons for the delay [1] Group 2 - By September 30, 2025, Wuhan Yitong must terminate its agency agreement for hydrochloride poppy alkaloid raw materials with Qinghai Pharmaceutical and cannot execute related agreements until this is resolved [2] - The ultimate controller of Wuhan Yitong has committed not to engage in any future operator concentration in the fields of hydrochloride poppy alkaloid raw materials and injections [2] - The market regulator retains the authority to supervise and inspect Wuhan Yitong and its ultimate controller's compliance with these obligations [2]